Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Mar;91(3):506–509. doi: 10.1111/j.1365-2249.1993.tb05932.x

Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease.

A Rocca 1, A A Khamlichi 1, P Aucouturier 1, L H Noël 1, L Denoroy 1, J L Preud'homme 1, M Cogné 1
PMCID: PMC1554718  PMID: 7680298

Abstract

Although structural abnormalities of monoclonal immunoglobulin light chains (LC) are suspected to play a determinant role in non-amyloid light chain deposition disease (LCDD), this condition is as yet poorly documented at the molecular level, since only three sequences have been reported to date. In a case of myeloma-associated LCDD, the patient's urine contained an unglycosylated kappa Bence Jones protein made up of dimers and monomers with an apparent molecular mass of 25,000 which was assigned to the V kappa I subgroup by N-terminal amino acid sequencing. The complete variable region sequence of the monoclonal kappa chain produced by the malignant plasma cells was amplified by polymerase chain reaction (PCR) using small amounts of material obtained by bone marrow aspiration. The sequence of three independently amplified cDNA clones derived from a normal-sized kappa messenger RNA was identical to that of the urinary kappa chain. The kappa mRNA had an overall normal structure made up of a V kappa I sequence rearranged to J kappa I. Several unusual features of the variable region (the first complete V kappa I sequence reported in LCDD) included three substitutions that introduced hydrophobic residues at spatially close positions. The strategy associating N-terminal sequence determination and cDNA cloning by PCR could help in accumulating new sequence data and improving our understanding of LCDD pathogenesis.

Full text

PDF
506

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aucouturier P., Khamlichi A. A., Preud'homme J. L., Bauwens M., Touchard G., Cogné M. Complementary DNA sequence of human amyloidogenic immunoglobulin light-chain precursors. Biochem J. 1992 Jul 1;285(Pt 1):149–152. doi: 10.1042/bj2850149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellotti V., Stoppini M., Merlini G., Zapponi M. C., Meloni M. L., Banfi G., Ferri G. Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. Biochim Biophys Acta. 1991 Oct 21;1097(3):177–182. doi: 10.1016/0925-4439(91)90032-5. [DOI] [PubMed] [Google Scholar]
  3. Bentley D. L., Rabbitts T. H. Human immunoglobulin variable region genes--DNA sequences of two V kappa genes and a pseudogene. Nature. 1980 Dec 25;288(5792):730–733. doi: 10.1038/288730a0. [DOI] [PubMed] [Google Scholar]
  4. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992 Apr;6(2):323–346. [PubMed] [Google Scholar]
  5. Cogné M., Bakhshi A., Korsmeyer S. J., Guglielmi P. Gene mutations and alternate RNA splicing result in truncated Ig L chains in human gamma H chain disease. J Immunol. 1988 Sep 1;141(5):1738–1744. [PubMed] [Google Scholar]
  6. Cogné M., Preud'homme J. L., Bauwens M., Touchard G., Aucouturier P. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest. 1991 Jun;87(6):2186–2190. doi: 10.1172/JCI115252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cogné M., Silvain C., Khamlichi A. A., Preud'homme J. L. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood. 1992 May 1;79(9):2181–2195. [PubMed] [Google Scholar]
  8. Epp O., Lattman E. E., Schiffer M., Huber R., Palm W. The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution. Biochemistry. 1975 Nov 4;14(22):4943–4952. doi: 10.1021/bi00693a025. [DOI] [PubMed] [Google Scholar]
  9. Esch F. S. Polypeptide microsequence analysis with the commercially available gas-phase sequencer. Anal Biochem. 1984 Jan;136(1):39–47. doi: 10.1016/0003-2697(84)90305-1. [DOI] [PubMed] [Google Scholar]
  10. Gerlag P. G., Koene R. A., Berden J. H. Renal transplantation in light chain nephropathy: case report and review of the literature. Clin Nephrol. 1986 Feb;25(2):101–104. [PubMed] [Google Scholar]
  11. Hewick R. M., Hunkapiller M. W., Hood L. E., Dreyer W. J. A gas-liquid solid phase peptide and protein sequenator. J Biol Chem. 1981 Aug 10;256(15):7990–7997. [PubMed] [Google Scholar]
  12. Hieter P. A., Maizel J. V., Jr, Leder P. Evolution of human immunoglobulin kappa J region genes. J Biol Chem. 1982 Feb 10;257(3):1516–1522. [PubMed] [Google Scholar]
  13. Khamlichi A. A., Aucouturier P., Silvain C., Bauwens M., Touchard G., Preud'homme J. L., Nau F., Cogné M. Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1992 Jan;87(1):122–126. doi: 10.1111/j.1365-2249.1992.tb06424.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  15. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem. 1987 Jul 25;262(21):10035–10038. [PubMed] [Google Scholar]
  16. Picken M. M., Frangione B., Barlogie B., Luna M., Gallo G. Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization. Am J Pathol. 1989 Apr;134(4):749–754. [PMC free article] [PubMed] [Google Scholar]
  17. Prend'homme J. L., Buxbaum J., Scharff M. D. Mutagenesis of mouse myeloma cells with 'Melphalan'. Nature. 1973 Oct 12;245(5424):320–322. doi: 10.1038/245320a0. [DOI] [PubMed] [Google Scholar]
  18. Preud'Homme J. L., Morel-Maroger L., Brouet J. C., Mihaesco E., Mery J. P., Seligmann M. Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol. 1980 Dec;42(3):545–553. [PMC free article] [PubMed] [Google Scholar]
  19. Preud'homme J. L., Morel-Maroger L., Brouet J. C., Cerf M., Mignon F., Guglielmi P., Seligmann M. Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med. 1980 Nov;69(5):703–710. doi: 10.1016/0002-9343(80)90421-0. [DOI] [PubMed] [Google Scholar]
  20. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  21. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stevens F. J., Solomon A., Schiffer M. Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology. Biochemistry. 1991 Jul 16;30(28):6803–6805. doi: 10.1021/bi00242a001. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES